Armando L. G.
- Country
- Spain
- Department
- Hematology
Research Overview
- Safety and Tolerability Assessment of Odronextamab and Cemiplimab in Adult Patients with B-Cell Non-Hodgkin’s Lymphoma
- Efficacy and Safety Evaluation of Glofitamab with Gemcitabine and Oxaliplatin Versus Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy A – Relapsed/Refractory Waldenstrom Macroglobulinemia
Data & Insights
Has run more than one trial at 122 of 280 partner sites.
Specializations
Lymphoma Research Focus
This investigator specializes in B-cell lymphoma treatments, with particular emphasis on diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma therapeutic approaches.
- Relapsed/Refractory DLBCL Management
- First-line DLBCL Treatment
- Advanced Follicular Lymphoma Care
Clinical interests extend to innovative therapeutic combinations including immunotherapy and targeted agents.
Rare B-Cell Malignancies
The investigator has extensive experience in treating rare hematologic conditions, including Burkitt lymphoma, Waldenstrom macroglobulinemia, and hairy cell leukemia.
- Richter Transformation Treatment
- Refractory B-Cell Disorders
- Novel Therapeutic Approaches
Expertise includes evaluation of advanced cellular therapies for rare lymphoid malignancies.
Therapeutic Innovation
Focus areas include CAR T-cell therapy applications and targeted immunotherapy combinations for hematologic malignancies.
- Gene-Modified T Cell Therapies
- Novel Drug Combinations
- Long-term Treatment Outcomes
Specialized in evaluating innovative treatment approaches for both common and rare blood cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.